Article Per Year (5 Year)
p-Index From 2020 - 2025
1.971
P-Index
This Author published in this journals
All Journal Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Indonesian Journal of Urology Paediatrica Indonesiana Indonesian Journal of Cancer Indonesian Journal of Biomedicine and Clinical Sciences
Indrawarman Soeroharjo
Division Of Urology, Department Of Internal Medicine, Faculty Of Medicine, Public Health And Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 15 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 15 Documents
Search

 1   2 
Prostat cancer profile in Dr. Sardjito General Hospital Yogyakarta Yurisal Akhmad Dany; Ahmad Zulfan Hendri; Indrawarman Soerohardjo
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 53, No 3 (2021)
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (514.187 KB) | DOI: 10.19106/JMedSci005303202104

Abstract

Prostate  cancer  is  the  fourth  most  common  type  of  non-skin  malignancy  in  male malignancies. In Indonesia, the definitive data are unreported, however, Globocan  reported  prostate  cancer  in  5th  place  in  2018.    Early  diagnosis  and  treatment  of  this  cancer  are  associated  with  reduced  mortality  rates.  This  study aimed to investigate the profile of prostate cancer in Dr. Sardjito General Hospital,  Yogyakarta,  Indonesia.  A  retrospective  study  involving  a  total  of  90  prostate cancer patients who underwent follow-up care at Dr. Sardjito General Hospital, Yogyakarta in the period of 2015 to 2020 was conducted. Data of the patients from their medical records consisted of age, gender, prostate volume, PSA  level,  testosterone  level,  hydronephrosis,  TURP  history,  histopathology  results,  Gleason  scores,  ISUP  grade,  and  staging  TNM  were  collected.  The  average of patients age was 67 ±10.4 y.o. where 22 (24.4%) patients aged < 60 y.o., 34 (37.8%) patients aged 61-70 y.o. and 34 (37.8%) patients aged >70 y.o. Almost of all patients (87 patients or 97.8%) were diagnosed as adenocarcinoma. Most of patients (73 patients or 81.4%) had prostate volume (TAUS) > 30 cm3 with the median at diagnosis was 51 cm3 (38.3 – 104.4). Furthermore, the median of PSA for diagnosis was 234.4 (94.4 – 1720.3) ng/mL and the median of testosterone level  at  diagnosis  was  317  (10  -  384)  ng/dL.  In  conclusion,  most  patients  with  prostate  cancer  are  identified  as  adenocarcinoma  with  metastatic  stage.  In  general, the prostate cancer patients age more than 61 years old with prostate volume  (TAUS)  >  30  cm3.  In  addition,  prostate  volume  and  testosterone  level  can be routinely used as initial screening and periodic assessment to evaluate prognosis and disease progression.
Progressive Muscular Dystrophy (Duchenne Type) (Case Report) Soelatin Winarno; Indrawarman Indrawarman; Sabdo Waloejo; Lydia Kristianti
Paediatrica Indonesiana Vol 16 No 9-10 (1976): September - October 1976
Publisher : Indonesian Pediatric Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (493.556 KB) | DOI: 10.14238/pi16.9-10.1976.361-4

Abstract

Clinical findings of two brothers suffering from progressive muscular dystrophy pseudohypertrophic type according to Duchenne are reported. Literatures dealing with its clinical classification, biochemical disturbances, hypotheses of the pathogenesis, management of treatment, mode of action of A.T.P. and the pedigree have been briefly reported. Progressive Muscular Dystrophy is a progressive disease affecting voluntary muscles; It is characterized by a decreased strength in the affected muscles with rapid or slow gradual progression. About 45% of the patients gave a history that at least another member of the family is affected by the disease. Pseudohypertrophic form (Duchenne type) is usually inherited as a recessive factor, often sexlinked.
Over-Expression of Osteopontin as Potential Predictive Biomarker for Bladder Cancer Treatment Andy Zulfiqqar; Indrawarman Soerohardjo; Sumadi Lukman Anwar
Indonesian Journal of Cancer Vol 14, No 2 (2020): June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v14i2.709

Abstract

Background: Current options for management of bladder cancer (BCa) still depend on traditional clinical determinants of stage and histological grade which often do not reflect the biological entity of the tumors. Therefore, new biomarkers are required to better determine suitable treatments for different types of bladder cancers. Recent research has shown osteopontin (OPN) expressions correlate with clinic-pathological variables and outcomes of bladder cancer. This study aimed to evaluate the expression of OPN in the Indonesian population, and it’s potential role as an immune-targeting therapy of BCa. Methods: Total RNAs from formalin-fixed paraffin-embedded tissues were extracted from 49 patients with bladder cancer consisting of normal histopathology (n = 4), chronic cystitis (n = 15), non-muscle-invasive bladder cancer (NMIBC, n = 15), and muscle-invasive breast cancer (MIBC, n = 15). The expression of OPN was measured using reverse transcription-polymerase chain reaction. Results: The baseline clinical and histo-pathological characteristics were not statistically different. The expression of OPN was statistically higher in bladder cancer compared to normal histology tissues (P < .001). The expression of OPN was statistically higher in MIBC compared to NMIBC (P < .001). Conclusions: The expression of OPN was significantly higher in bladder cancer and compared to NIMBC, the OPN expression in MIBC was significantly higher rendering the potential role of OPN expression as a surrogate biomarker marker to determine suitable treatment options for patients with bladder cancer.
The correlation between interleukin-4 (IL-4) and programmed cell death-ligand 2 (PD-L2) expression with clinicopathological characteristics on prostate cancer Prakoso, Ragil Unggul; Danarto, Raden; Soerohardjo, Indrawarman; Dany, Yurisal Akhmad; Dwianingsih, Ery Kus
Indonesian Journal of Biomedicine and Clinical Sciences Vol 56 No 01 (2024)
Publisher : Published by Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/inajbcs.v56i01.12438

Abstract

Prostate cancer (PCa) is the most frequent cancer diagnosed worldwide and the second most common malignancy in men. IL-4 is one of cytokines related to the inflammation process. An increase level of IL-4 in patients with PCa might be related to progression to castrate-resistance prostate cancer. Programmedcell death-ligand 2 (PD-L2) plays an important role in the anti-tumor immune system, however the exact mechanism is not fully understood. This study aimed to investigate the correlation between IL-4 and PD-L2 expression with the clinicopathological characteristic of PCa. The IL-4 and PD-L2 examinations wereperformed using quantitative real-time polymerase chain reaction (qRT-PCR) while clinicopathological characteristics were described by the Gleason score and International Society of Urological Pathology (ISUP) grade. Data collected were then analyzed using Pearson and Spearman test. In total, 20 patients withPCa tissue were collected between 2015 and 2020. The mean level of IL-4 and PDL2 were higher in metastatic PCa/M-PCa (105.64 and 665.42 ng/mL) compared to non-metastatic PCa/NM-PCa (41.62 and 215.06 ng/mL). A significant difference with medium correlation between IL-4 and PD-L2 with Gleason score and ISUPgrade was observed on all samples (p = 0.035 and 0.045; r = 0.454 and 0.473). However, no significant difference with weak correlation was observed on each group (p = 0.136 and 0.858; r = 0.065 and 0.506). Interestingly, there was a significant difference with very strong correlation observed between IL-4 andPD-L2, both on all samples (p = 0.001; r = 0.955) and on each group (p = 0.001 and 0.001; r = 0.917 and 0.955). In conclusion, there is a correlation between IL-4 and PD-L2 with the clinicopathological characteristics of PCa.
Cytotoxic T lymphocyte associated antigen-4 (CTLA4) expression with renal cell carcinoma subtype and staging Sangundo, Muhammad Faham; Soerohardjo, Indrawarman; Heriyanto, Didik Setyo
Indonesian Journal of Biomedicine and Clinical Sciences Vol 56 No 2 (2024)
Publisher : Published by Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/inajbcs.v56i2.13467

Abstract

In Indonesia, approximately 45% of renal cell carcinoma (RCC) patients are at an advanced stage that requires checkpoint inhibition combination immunotherapy. Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is associated with poor prognosis of RCC and it is the first checkpoint developed in cancer immunotherapy. This study aimed to investigate CTLA-4 expression among RCC subtypes and staging. Formalin fixed paraffin embedded (FFPE) tissue of RCC patients from 2018-2020 were obtained from the Department of Anatomical Pathology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta. Expression of CTLA-4 among RCC subtypes and stage was measured using quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and compared. Among the 40 patients involved in this study, the CTLA-4 expression was higher in papillary RCC/pRCC (95.88 + 31.58) compared to clear cell RCC/ccRCC (90.94 + 43.05). However, no significantly different in CTL-4 expression based on histologic subtypes and tumor stage (p>0.05). In conclusion, neither the histologic subtype nor the tumor stage of RCC can be predicted by CTLA-4 expression.
Co-Authors Ahmad Zulfan Ahmad Zulfan Hendri Alharsya Franklyn Ruckle Andy Zulfiqqar Andy Zulfiqqar Brodjonegoro, Sakti R Danarto, Raden Didik Setyo Heriyanto Ery Kus Dwianingsih Frannata, Lucky H R Danarto Hariwibowo, Rinto Hendri, Ahmad Z Hendri, Ahmad Z. Indah S. Widyahening Indra Bayu Nugroho, Indra Bayu Krisna, Muhammad Sidharta Lydia Kristianti Muhammad Puteh Mauny Nur Rasyid Ponco Birowo Prahara Yuri Prakoso, Ragil Unggul Prawito Singodimedjo Prayogo, Dwi Raden Danarto Risan, Muhammad Sabdo Waloejo Sangundo, Muhammad Faham Soelatin Winarno Sumadi Lukman Anwar Yurisal Akhmad Dany Yurisal Akhmad Dany Zulfikar Ali, Zulfikar Zulfiqqar, Andy